Pharma 2020: Marketing the future |
Print this page
Email to a colleague
|
Pharma 2020: Marketing the future
Adobe PDF Format
February 2009
Pharma 2020: Marketing the future - Which path will you take? The third in the Pharma 2020 series, outlines a confluence of dynamics that lead to a new marketing and sales system with a smaller, more agile and smarter sales force. The pharma industry is no longer being rewarded for incremental innovation, me-too products and selling the most pills. Companies will need to demonstrate that their brand adds value to patients and they will have to offer a package of products and health services that the market not only wants and needs but is willing to pay a premium for. The paper highlights some very strong facts related to the need for Pharma to change its marketing and sales functions in order so sustain future growth and performance.
© 2010 PricewaterhouseCoopers. All rights reserved. "PricewaterhouseCoopers" and "PwC" refer to the network of member firms of PricewaterhouseCoopers International Limited (PwCIL). Each member firm is a separate legal entity and does not act as agent of PwCIL or any other member firm. Neither PwCIL nor any member firm is responsible or liable for the acts or omissions of any other member firm nor control the exercise of another member firm's professional judgment or bind another member firm or PwCIL in any way. PricewaterhouseCoopers. All rights reserved. PricewaterhouseCoopers refers to the network of member firms of PricewaterhouseCoopers International Limited, each of which is a separate and independent legal entity.
Bookmark with: